Breast最新文献

{"title":"Advancing the legal rights of people with advanced breast cancer: a global expert review and call-to-action for 2025–2035 (Goal 10)","authors":"Sarah McHutchison ,&nbsp;Tarishi Desai ,&nbsp;Hayley Jones ,&nbsp;Georgia Attfield ,&nbsp;Alexandra Lewis ,&nbsp;Fatima Cardoso","doi":"10.1016/j.breast.2025.104613","DOIUrl":"10.1016/j.breast.2025.104613","url":null,"abstract":"<div><div>A diagnosis of advanced breast cancer (ABC) can be life-altering, presenting challenges that extend far beyond the clinical domain. Among these challenges is the ability to continue or return to work, a decision often influenced by financial necessity, social support, and the psychological desire for normalcy. Yet, systemic barriers such as treatment-related side effects, physical and cognitive impairments, and workplace stigma frequently hinders people with ABC from maintaining employment. The right to work is fundamental to dignity, independence, and quality of life, but for people with ABC this right is too often denied due to a lack of workplace support and insufficient legal protection.</div><div>This manuscript explores the current landscape and future opportunities to advance the legal rights of people with ABC. It summarizes research conducted for the ABC Global Alliance's Global Decade Report 2.0. The main findings are: a) ABC diagnosis severely limits work participation and employment retention; b) Legal protections for ABC patients and informal caregivers (often unpaid family members and friends) remain inconsistent globally; c) Flexible work policies can reduce economic loss and support workplace inclusion; d) ABC informal caregiver burden causes significant economic and social impact.</div><div>The findings from the ABC Global Alliance's Global Decade Report 2.0 have informed the development of a new ABC Global Charter. The ABC Global Charter 2.0 defines ten new achievable and measurable goals for the decade 2025–2035, aiming at improving the lives of people living with ABC worldwide.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104613"},"PeriodicalIF":7.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145619943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathologic complete response in TNBC: A shield against recurrence, but not the brain?","authors":"Kadri Altundag","doi":"10.1016/j.breast.2025.104606","DOIUrl":"10.1016/j.breast.2025.104606","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104606"},"PeriodicalIF":7.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145312443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meeting the informational needs of people with advanced breast cancer: a global expert review and call-to-action for 2025–2035 (Goal 6)","authors":"Anna Cabanes ,&nbsp;Jenny Gilchrist ,&nbsp;Marzia Zambon ,&nbsp;Maya Gilbert ,&nbsp;Alexandra Lewis ,&nbsp;Georgia Attfield ,&nbsp;Fatima Cardoso","doi":"10.1016/j.breast.2025.104611","DOIUrl":"10.1016/j.breast.2025.104611","url":null,"abstract":"<div><div>For people living with advanced breast cancer (ABC), the complexities of making treatment decisions, adhering to medication regimens, and balancing the social and personal aspects of the disease can be overwhelming. People with ABC need comprehensive information and resources to understand their disease, prognosis, and treatment options. However, this information is often difficult to access, interpret or navigate, leaving many feeling confused, frustrated and helpless<strong>.</strong></div><div>This manuscript evaluates the global ABC information landscape and its evolution since 2015, it analyzes the ongoing challenges faced by people with ABC, and outlines recommendations for the ABC community over the next decade. It summarizes research conducted for the ABC Global Alliance's Global Decade Report 2.0. The main findings are: a) The availability of ABC information has increased, but topics remain limited; b) ABC information from healthcare professionals is often limited to clinical topics; c) Patient advocacy groups are now crucial, trusted sources of ABC information; d) Online ABC information presents both opportunities and challenges; e) Global disparities in access to some topics of ABC information persist.</div><div>The findings from the ABC Global Alliance's Global Decade Report 2.0 have informed the development of a new ABC Global Charter. The ABC Global Charter 2.0 defines ten new achievable and measurable goals for the decade 2025–2035, aiming at improving the lives of people living with ABC worldwide.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104611"},"PeriodicalIF":7.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensuring access to multidisciplinary care in advanced breast cancer: a global expert review and call-to-action for 2025–2035 (Goal 4)","authors":"Shani Paluch-Shimon ,&nbsp;Laura Biganzoli ,&nbsp;Julie Torode ,&nbsp;Ginny Mason ,&nbsp;Sung-Bae Kim ,&nbsp;Runcie C.W. Chidebe ,&nbsp;Merel van Klinken ,&nbsp;Georgia Attfield ,&nbsp;Alexandra Lewis ,&nbsp;Fatima Cardoso","doi":"10.1016/j.breast.2025.104609","DOIUrl":"10.1016/j.breast.2025.104609","url":null,"abstract":"<div><div>Despite remarkable advances in the management of advanced breast cancer (ABC), profound disparities persist in outcomes and access to quality care globally. A multidisciplinary approach, where specialists collaborate on diagnosis, treatment planning, care continuity, and timely referrals, is widely recognized as the gold standard in ABC management and has been shown to lead to more accurate diagnoses, individualized treatment plans, and improved patient outcomes. Depending on the healthcare system, a multidisciplinary team (MDT) may include a medical oncologist, a radiation/clinical oncologist, radiologist, pathologist, surgeon, specialist nurse, allied healthcare professionals, and administrative staff. A multidisciplinary approach to ABC care is recommended by international guidelines and endorsed by leading bodies such as the European Society of Breast Cancer Specialists (EUSOMA).</div><div>This manuscript explores the current multidisciplinary care landscape in ABC, highlighting progress made, persistent challenges, and future directions. It summarizes research conducted for the ABC Global Alliance's Global Decade Report 2.0. The main findings are: a) New EUSOMA quality indicators set benchmarks for multidisciplinary ABC care; b) Most national guidelines now recommend multidisciplinary care for ABC; c) Surveys reveal uneven multidisciplinary team access, notably in low-income settings; d) Telemedicine and virtual MDTs expand access to ABC expertise; e) Palliative care remains poorly integrated in many MDTs globally.</div><div>The findings from the ABC Global Alliance's Global Decade Report 2.0 have informed the development of a new ABC Global Charter. The ABC Global Charter 2.0 defines ten new achievable and measurable goals for the decade 2025–2035, aiming at improving the lives of people living with ABC worldwide.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104609"},"PeriodicalIF":7.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supplemental imaging modalities for breast cancer screening in women with dense breasts: A systematic review with economic considerations","authors":"Sinéad N. Duggan ,&nbsp;Mohammad Azharuddin ,&nbsp;Rodolfo Hernández ,&nbsp;Clare Robertson ,&nbsp;David Cooper ,&nbsp;Emma McCall ,&nbsp;Paul Manson ,&nbsp;Gianni Virgili ,&nbsp;Mike Clarke ,&nbsp;Shaun Treweek ,&nbsp;Miriam Brazzelli","doi":"10.1016/j.breast.2025.104668","DOIUrl":"10.1016/j.breast.2025.104668","url":null,"abstract":"<div><h3>Background</h3><div>Underdiagnosis of breast cancer is a concern for women with dense breasts. This systematic review and meta-analysis evaluates the performance and cost-effectiveness of supplementary imaging modalities plus standard mammography, versus mammography alone, for detecting breast cancer in women with dense breasts.</div></div><div><h3>Methods</h3><div>We searched MEDLINE, Embase, Scopus, Cochrane Database, Web of Science, and CENTRAL for English-language studies published January 2014 to November 2024. Eligible studies compared the performance of a supplementary imaging modality with standard mammography in terms of cancer detection rate (CDR) in women with dense breasts undergoing screening. Risk of bias was assessed using QUADAS-2/QUADAS-C. Screening, data extraction, and quality assessment was conducted by one reviewer and checked by a second reviewer. PROSPERO: CRD42024550250.</div></div><div><h3>Results</h3><div>Out of 1740 search results, 36 studies met the inclusion criteria. Versus mammography alone, magnetic resonance imaging (MRI) identified 18·92 (95 % CI 15·41-22·43) additional cancers per 1000 screenings while digital breast tomosynthesis (DBT), automated breast ultrasound (ABUS), and handheld ultrasound (HHUS) detected 1·69 (95 % CI 0·81-2·58), 2·3 (95 % CI 1·28-3·33), and 2·57 (95 % CI 0·99-4·14) additional cancers, respectively. One study of contrast-enhanced mammography (CEM) reported a CDR comparable to MRI. Economic modelling studies revealed heterogeneous results, with MRI showing potential under specific model assumptions.</div></div><div><h3>Concluding statement</h3><div>Standard mammography often fails to detect cancers in women with dense breasts. Supplementary MRI provides better detection than DBT, ABUS, and HHUS. CEM seems comparable to MRI, based on limited evidence. These findings should be considered in future screening policy reviews for women with dense breasts.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104668"},"PeriodicalIF":7.9,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study","authors":"Nadia Bianco ,&nbsp;Carmine Valenza ,&nbsp;Monica Milano ,&nbsp;Roberta Multinu ,&nbsp;Elena Battaiotto ,&nbsp;Matteo Cavallone ,&nbsp;Giulia Malvezzi ,&nbsp;Dario Trapani ,&nbsp;Paolo Della Vigna ,&nbsp;Guido Bonomo ,&nbsp;Gianluca M. Varano ,&nbsp;Daniele Maiettini ,&nbsp;Maria Giovanna Pitoni ,&nbsp;Claudia Sangalli ,&nbsp;Elisabetta Munzone ,&nbsp;Giuseppe Curigliano ,&nbsp;Marco A. Colleoni ,&nbsp;Franco Orsi","doi":"10.1016/j.breast.2025.104667","DOIUrl":"10.1016/j.breast.2025.104667","url":null,"abstract":"<div><h3>Background</h3><div>Patients with visceral oligoprogressive and oligopersistent metastatic breast cancer (mBC) may benefit from metastasis-directed thermal ablation (TA) to all sites of metastasis, while maintaining the same systemic treatment, in order to delay the time to treatment failure (TTF). This study aims to assess the outcomes provided by this multimodal strategy.</div></div><div><h3>Methods</h3><div>We conducted a single-center, cohort study including consecutive patients with visceral oligoprogressive and oligopersistent mBC as per ESTRO/EORTC criteria, who underwent TA to all sites. Oligoprogression was defined as progressive disease in ≤5 metastatic sites with at least one other metastatic site maintaining the disease control; oligopersistence as ≤5 persistent lesions after systemic therapy. The main endpoint was post-TA progression-free survival (pTA-PFS).</div></div><div><h3>Results</h3><div>43 patients with oligoprogressive (cohort A) and 43 with oligopersistent (cohort B) disease were included; 4 (5 %) reported a TA-related adverse event. Overall, 122 visceral lesions were treated. In cohort A, median PFS before oligoprogression was 14.9 months (95 % CI, 9.7–20.1). After TA, 32 patients continued the same systemic treatment and 11 switched therapy; pTA-PFS was 9.1 months (95 % CI, 4.8–13.4), unchanged after excluding patients who switched systemic therapy. In cohort B, median PFS before oligopersistence was 7.8 months (95 % CI, 7.4–8.3). After TA, 35 patients continued the same systemic treatment, while 8 de-intensified to maintenance therapy; pTA-PFS was 16.7 months (95 % CI, 11.1–22.2).</div></div><div><h3>Conclusion</h3><div>Selected patients with visceral oligoprogressive and oligopersistent mBC appear to benefit from TA and systemic treatment continuation or modulation. This strategy can be implemented for selected patients in the framework of a multidisciplinary tumor board's shared decision.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104667"},"PeriodicalIF":7.9,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines","authors":"Eline E.F. Verreck ,&nbsp;Emily L. Postma ,&nbsp;Tanja Oostergo ,&nbsp;Joyce Meijer ,&nbsp;Anouk Eijkelboom ,&nbsp;Sabine Siesling ,&nbsp;Dimitris Rizopoulos ,&nbsp;Thijs van Dalen ,&nbsp;José H. Volders","doi":"10.1016/j.breast.2025.104664","DOIUrl":"10.1016/j.breast.2025.104664","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvant systemic therapy has improved breast cancer outcomes over the past decades. Following the distinction of molecular subtypes and the introduction of gene expression profiling and prognostic tools, chemotherapy is less frequently recommended for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. However, recommendations for endocrine therapy (ET) remained unchanged. This study examines ET trends among HR+/HER2- patients in the Netherlands and factors influencing these trends.</div></div><div><h3>Methods</h3><div>All HR+/HER2- patients diagnosed between 2012 and 2022 who underwent surgery were selected from the Netherlands Cancer Registry. Patients were categorized by ET guideline indications: no indication; indication based on pathological, postoperative TNM-stage/grade; or indication based on clinical TNM-stage/grading on biopsy warranting neoadjuvant chemotherapy (NAC). The ET benefit was estimated for all patients using the PREDICT 2.0 tool. Logistic regression was used to identify factors associated with ET initiation.</div></div><div><h3>Results</h3><div>The study included 127,610 HR+/HER2- patients. The proportion starting ET according to guideline recommendations decreased from 91.2 % (2012) to 79.3 % (2022), with those who did not initiate ET having a lower PREDICT-estimated benefit (1.0 %) compared to those who did (1.5 %). Reduced ET initiation was associated with age 30–39, age &gt;80, and treatment in academic hospitals. In 2022, ET initiation varied by up to 19 percentage points across regions, while the PREDICT-estimated benefit showed no clinically relevant difference (ranging from 1.3 % to 1.5 %).</div></div><div><h3>Conclusion</h3><div>Despite unchanged guideline recommendations, fewer patients started ET over time. This trend, and regional variation, suggests that a more reticent approach by physicians to initiating ET for HR+/HER2- breast cancer may be contributing to it.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104664"},"PeriodicalIF":7.9,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145666945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study","authors":"Renata Duchnowska ,&nbsp;Katarzyna Soter ,&nbsp;Katarzyna Pogoda ,&nbsp;Jolanta Smok-Kalwat ,&nbsp;Aleksandra Grela-Wojewoda ,&nbsp;Karolina Winsko-Szczęsnowicz ,&nbsp;Agnieszka Kowalewska-Felczak ,&nbsp;Marek Szwiec ,&nbsp;Iwona Danielewicz ,&nbsp;Joanna Streb ,&nbsp;Tomasz Lewandowski ,&nbsp;Bartosz Szymanowski ,&nbsp;Joanna Kiszka ,&nbsp;Barbara Radecka ,&nbsp;Ewa Kalinka ,&nbsp;Bartosz K. Sobocki ,&nbsp;Maria Litwiniuk ,&nbsp;Aleksandra Łacko ,&nbsp;Anna Bałata ,&nbsp;Justyna Żubrowska ,&nbsp;Jacek Jassem","doi":"10.1016/j.breast.2025.104665","DOIUrl":"10.1016/j.breast.2025.104665","url":null,"abstract":"<div><h3>Background</h3><div>Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first- and second-line treatments for hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC). Real-world data (RWD) may inform the optimal use of these agents in routine practice.</div></div><div><h3>Patients and methods</h3><div>The multicenter, population-based POLiCDK study compared progression-free survival (PFS), second PFS, and overall survival (OS) in ABC patients with HR+/HER2− ABC treated with palbociclib (PAL), ribociclib (RIB), or abemaciclib (ABE) in first- or second-line ET settings at 16 Polish centers between September 2017 and January 2025. Analyses were stratified by endocrine sensitivity/resistance, and stabilized inverse probability of treatment weighting was used to balance baseline characteristics.</div></div><div><h3>Results</h3><div>Among 2063 patients (701 PAL, 968 RIB, 394 ABE), 1583 (76.7 %) received CDK4/6i in the first-line and 480 (23.3 %) in the second-line setting. Overall, 927 (44.9 %) had <em>de novo</em> ABC; 819 (39.7 %) were endocrine-naïve, 158 (8.9 %) primary resistant, and 808 (39.2 %) secondary resistant. Median follow-up was 35.9, 24.1, and 21.4 months for PAL, RIB, and ABE, respectively. In endocrine-naïve patients, PFS did not differ significantly between CDK4/6i combined with aromatase inhibitors (AIs). In secondary endocrine-resistant disease, RIB and ABE outperformed PAL with AI combinations, whereas outcomes with fulvestrant were similar. In second-line therapy, all three CDK4/6i showed comparable results. Adjusted hazard ratios confirmed these trends without consistent superiority of any single agent.</div></div><div><h3>Conclusions</h3><div>Endocrine sensitivity/resistance and ET partner were major determinants of outcome with CDK4/6i plus ET in HR+/HER2− ABC, informing individualized treatment selection and sequencing.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104665"},"PeriodicalIF":7.9,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant","authors":"Maartje A.C. Schreurs ,&nbsp;Muriel A. Adank ,&nbsp;Bernadette A.M. Heemskerk-Gerritsen ,&nbsp;Antoinette Hollestelle ,&nbsp;Nyrée Smallenbroek ,&nbsp;Christi J. van Asperen ,&nbsp;Margreet G.E.M. Ausems ,&nbsp;Irma van de Beek ,&nbsp;Geertruida H. de Bock ,&nbsp;Ingrid Boere ,&nbsp;Liselotte P. van Hest ,&nbsp;Kim J.A.F. van Kaam ,&nbsp;Linda de Munck ,&nbsp;Janet R. Vos ,&nbsp;Agnes Jager ,&nbsp;Marjanka K. Schmidt ,&nbsp;Maartje J. Hooning ,&nbsp;Hebon","doi":"10.1016/j.breast.2025.104666","DOIUrl":"10.1016/j.breast.2025.104666","url":null,"abstract":"<div><h3>Purpose</h3><div>Germline <em>CHEK2</em> c.1100delC-associated breast cancer (BC) patients have been reported with worse prognosis than patients without the variant. However, results are based on older cohorts and treatment regimens. As part of the Hebon-CHEK2 study, we aim to study prognosis in a Dutch cohort of genetically tested ER-positive BC patients diagnosed from 2006 onwards.</div></div><div><h3>Methods</h3><div>All patients underwent genetic testing based on personal and family history risk, and data on BC outcomes were collected. Hazard ratios (HRs) and 95 % confidence intervals (CI) for the association of <em>CHEK2</em>-status with prognosis were estimated via delayed entry Cox regression models, adjusted for age and year of diagnosis, tumor size, nodal status, and primary treatment regimens. Furthermore, we meta-analyzed our results with previous studies.</div></div><div><h3>Results</h3><div>We included 480 <em>CHEK2</em> BC patients and 944 BC patients without the variant. Median follow-up was 6.0 years. Heterozygotes were more often diagnosed with small tumors, and lymph node positive disease. No significant difference was found for recurrent disease and distant disease-free survival, neither before 5 years (HR = 0.73; 95 %CI = 0.35–1.53 and HR = 0.99; 95 %CI = 0.44–2.21, respectively), nor after 5 years follow-up (HR = 0.29; 95 %CI = 0.06–1.28 and HR = 0.39; 95 %CI = 0.10–1.39, respectively). Also no significant difference in BC-specific survival (HR = 0.77; 95 %CI = 0.42–1.39) or overall survival (HR = 0.69; 95 %CI = 0.43–1.08) was found. Meta-analysis of our results with previous studies showed a worse BC-specific survival for heterozygotes.</div></div><div><h3>Conclusion</h3><div>In our study, with more recent years of diagnosis and treatment, we found no difference in prognosis, as opposed to previous studies. Further research is needed to validate our findings.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104666"},"PeriodicalIF":7.9,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the letter “Targeted digital intervention boosts endocrine therapy adherence in breast cancer patients with low health literacy”","authors":"Ilana Graetz","doi":"10.1016/j.breast.2025.104662","DOIUrl":"10.1016/j.breast.2025.104662","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104662"},"PeriodicalIF":7.9,"publicationDate":"2025-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}